Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B
Author Information
Author(s): Powdrill Megan H., Bernatchez Jean A., Götte Matthias
Primary Institution: McGill University
Conclusion
The review discusses the development of inhibitors targeting the NS5B polymerase of the hepatitis C virus and the challenges posed by drug resistance.
Supporting Evidence
- Over 170 million people are infected with hepatitis C virus worldwide.
- Current treatments are often ineffective and have severe side effects.
- Direct-acting antivirals target the NS5B polymerase, which is crucial for viral replication.
- Resistance to antiviral drugs can emerge quickly due to the virus's high mutation rate.
Takeaway
Scientists are working on new medicines to fight the hepatitis C virus, which can change a lot and make it hard to treat. Some of these new medicines target a specific part of the virus that helps it make copies of itself.
Methodology
This is a review article summarizing various classes of inhibitors targeting the NS5B polymerase and discussing their mechanisms and resistance issues.
Limitations
The review does not provide new experimental data but summarizes existing literature.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website